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S350 Poster Session IIto collect while no patient (0%) without previous LEN exposure
failed to collect, including 3 pts who received melphalan (p 5
0.105). Total number of CD34+ cells collected after 2 apheresis ses-
sions for group B 5 8.13x106/kg CD34+ cells and group A 5
3.34x106/kg CD34+ cells (p 5 0.06).
Conclusion: Chemomobilization with CTX + filgrastim yields ro-
bust PBSC collections irrespective of antecedent lenalidomide.
There was a trend towards lesser PBSC collection in LEN-treated
pts. Due to retrospective design and limited number of pts, further
research is needed to elucidate the effect of chemomobilization on
PBSC collection in LEN-treated pts.548
ADDITION OF RITUXIMAB TO EITHER BEAC OR BEAM IN THE PREPARA-
TIVE REGIMEN PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
IN PATIENTSWITH RELAPSED B-CELL NON-HODGKIN LYMPHOMA DOES
NOT ADD A SURVIVAL BENEFIT: A SINGLE CENTER EXPERIENCE
Williams, C.B., Loknath-Kumar, A., Divine, C.L., Aljitawi, O.A.,
Abhyankar, S., McGuirk, J.P., Ganguly, S. University of Kansas Medical
Center, Kansas City, KS
High-dose chemotherapy with carmustine, etoposide, cytosine
arabinoside, and melphalan (BEAM) or cyclophosphamide
(BEAC) followed by autologous hematopoietic stem cell
transplantation (ASCT) represents a standard therapy for many
patients with relapsed non-Hodgkin lymphoma (NHL). Whether
or not the addition of rituximab to either preparative regimen
(R-BEAM or R-BEAC) provides a benefit when given prior to
ASCT is unclear.
In an attempt to compare the efficacy, outcome, and toxicity of
BEAM (with or without rituximab) (n 5 36) and BEAC (with or
without rituximab) (n 5 21) in patients with NHL undergoing
ASCT, we retrospectively evaluated our center’s experience between
January 2007 and April 2010.
Out of 57 patients with relapsedNHL (median age 56 y; range 25-
72 y), 13 patients received BEAM (n 5 6) or BEAC (n 5 7) and 44
patients received R-BEAM (n 5 29) or R-BEAC (n 5 15) prior to
ASCT. All patients received rituximab containing salvage chemo-
therapy prior to transplantation.
The probability of disease-free survival (DFS) (80% in BEAM/
BEAC versus 70% in R-BEAM/R-BEAC group; p 5 0.69) and
overall survival (OS) (68% in BEAM/BEAC versus 80% in R-
BEAM/R-BEAC group; p 5 0.31) were comparable in both the
groups at 2 years. The probability of DFS (100% in BEAC ver-
sus 70% in R-BEAC group; p 5 0.55; and 71% in BEAM and
69% in R-BEAM group; p 5 0.47) and OS (100% in BEAC ver-
sus 92% in R-BEAC group; p 5 0.54; and 60% in BEAM and
80% in R-BEAM group; p 5 0.22) were also comparable at 2
years.
There was no difference in engraftment kinetics, grade III-IV tox-
icities, and average length of stay among the different groups.
In conclusion, the addition of rituximab to either preparative reg-
imen did not add any benefit to our patients undergoing ASCT for
B-cell NHL. It is possible that the universal use of rituximab with
prior salvage therapies might have abrogated the benefit of R-
BEAM/R-BEAC over BEAM/BEAC in this study. Whether or not
the addition of rituximab to the preparative regimens prior to
ASCT in patients with NHL truly adds any benefit needs to be stud-
ied in a larger prospective trial.549
APREPITANT: TREATMENT IN HAEMATOPOIETIC STEM CELL TRANS-
PLANTATION (HSCT) PATIENTS REFRACTORY TO FIRST AND SECOND
LINE ANTIEMETICS
Booth, D. Alfred Hospital, Melbourne, Victoria, Australia
Chemotherapy induced nausea and vomiting (CINV) is a distressing
side effect of the transplant procedure.Evidencebasedguidelines exist to
direct antiemetic prescribing for the prevention ofCINV.There ismin-
imal research providing guidance in the management patients with de-
layed emesis despite appropriate preventative strategies for CINV,
particularly afterHSCT. Aprepitant is a neurokinin-1 antagonist, which
incombinationwith5HT3antagonists anddexamethasone is effective inpreventingacuteanddelayedemesis afterhighlyemetogenicchemother-
apy. Aprepitant has been utilised in HSCT for prevention of CINV.
Aim:To assess the efficacy of aprepitant for the treatment of refrac-
tory emesis following HSCT.
Methods: Patients transplanted between Sept 2008 to Aug 2009,
experiencing more than one emetic episode or persistent nausea
score . 5/10 for more than 24 hours after review of antiemetic
therapy were included. Aprepitant was administered in addition
to current antiemetic therapy, as either 115mg IV daily or
125mg po stat and then 80 mg daily. The number of vomiting ep-
isodes, dry retches, nausea score on a ten point scale and break-
through antiemetic use was recorded at baseline and daily until
aprepitant ceased. A complete response was defined as no emetic
episodes, nausea score of 0/10 and no breakthrough antiemetic
use. Major response was defined as no emetic episodes with reduc-
tion of nausea score from baseline of at least 50% and partial
response as no emetic episodes but reduction in nausea score of
\ 50%.
Results: During the audit period 14 patients were prescribed apre-
pitant to treat emesis. A complete response was seen in 4/14
(28%), major response in 2/14 (14%) and partial response in 4/14
(28%) with an overall repose rate of 10/14 (71%). Responses were
sustained.
Conclusion: The addition of aprepitant can prevent emesis and
reduce nausea score in HSCT patients refractory to first and second
line antiemetic therapy.550
WHAT GOES UP MUST COME DOWN: VORICONAZOLE AND CYCLO-
SPORIN IN A PAEDIATRIC CORD AND MARROW TRANSPLANT UNIT
Wright, F.A.1,2, Daly, G.E.1,2, Song, E.Y.3,4, O’Brien, T.A.1,3,4 1Sydney
Children’s Hospital, Randwick, NSW, Australia; 2Sydney Children’s Hos-
pital, Randwick, NSW, Australia; 3Sydney Cord and Marrow Transplant
Program, Randwick, NSW, Australia; 4University of New South Wales,
Randwick, NSW, Australia
Voriconazole’s addition to the antifungal armamentarium has
been revolutionary. Its use in invasive fungal infection is of particular
utility in haematopoietic stem cell transplant (HSCT). Voriconazole
inhibits hepatic enzymes placing HSCT patients at risk of drug in-
teractions and toxicity from calcineurin inhibitors. Limited safety
and efficacy data exist for pediatric HSCT warranting investigation.
Objective: To investigate the safety and efficacy of voriconazole in
a pediatric HSCT unit 2008-10.
Method: A retrospective chart review of 43 consecutive allogeneic
transplants identified patients who received voriconazole from con-
ditioning until Day 100.
Results: 39 out of 43 (90.7%) patients are alive with a median follow
up of 17 months (1-32). There were no deaths from fungal infection.
42 of 43 patients received fungal prophylaxis. 35 patients were clas-
sified as low risk of infection and received fluconazole. 7 patients
were high risk due to pre transplant infection and received voricona-
zole. 1 patient on voriconazole developed mucormycosis and was ef-
fectively treated with posaconazole. 2 patients had suspected fungal
disease and had treatment with another agent. 4 patients continued
on prophylaxis with no demonstration of fungal disease. 13 of 43
(30.2%) fluconazole prophylaxis patients changed to voriconazole
treatment for suspected fungal infection with symptom resolution
in all patients.
Voriconazole was well tolerated. 1 patient withdrew due to toxic-
ity (confusion, rash). Hepatic dysfunction (GGT 2x normal) was sig-
nificantly higher in the voriconazole group (p\0.01). There was no
difference in transaminitis across the two groups.
On voriconazole initiation, cyclosporin dose was modified on
a risk adjusted basis. Cyclosporin level, creatinine, nephrotoxic
agents and GVHD were used to inform decision. There was no dif-
ference in cyclosporin levels or renal impairment (2 x baseline CR
urea) in the voriconazole group compared to those who received
other agents.
Conclusion: Safety and efficacy data are limited for new antifungals
when used with standard medications in pediatric HSCT. This small
series demonstrated voriconazole has acceptable toxicity and can be
prescribed without increasing cyclosporin toxicity. Currently, a dos-
ing algorithm is under evaluation to determine cyclosporin dose
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plexity with new agents and lack of pediatric data highlights a need
for collaboration between HSCT units.551
RETROSPECTIVE ANALYSIS OFWEEKLY INTRAVENOUS IMMUNOGLOBU-
LIN PROPHYLAXIS VERSUS INTRAVENOUS IMMUNOGLOBULIN BY IGG
LEVEL MONITORING IN HEMATOPOIETIC STEM CELL TRANSPLANT RE-
CIPIENTS
Howell, J.E.1, Gulbis, A.M.1, Qazilbash,M.H.2 1The University of Texas
MD Anderson Cancer Center, Houston, TX; 2The University of Texas
MD Anderson Cancer Center, Houston, TX
Background: Patients undergoing hematopoietic stem cell trans-
plant (HSCT) may have a higher incidence of infections due to sec-
ondary hypogammaglobulinemia. A recent meta-analysis evaluated
intravenous immune globulin (IVIG) in a prophylactic setting and
concluded routine use had no benefit in survival or infection preven-
tion inHSCT.The study suggestedmonitoring of IgG levels and re-
placing with IVIG in high risk patients.
Methods: All allogeneic HSCT patients who received prophylactic
IVIG 0.2 gm/kg IV onceweekly (n5 115) from admission to day +90
were compared to patients who received IVIG based on low IgG
levels (n5 114) between 1/09 and 8/09. The IgG levels were drawn
upon admission, day +30, day +60, and day +90. Utilization of IVIG,
incidence of veno-occulsive disease (VOD), graft versus host disease
(GVHD), and documented infections were recorded during the first
100 days after transplant.
Results:The weekly control group (n 5 115) had a median age of
49 compared to 54 years in the IVIG by level group (n 5 114).
No significant difference in type of transplant, except a higher
number of matched un-related donors (MUD) in the by level
group (62 vs 41, p 5 0.01). There were no significant differences
in occurrence of GVHD (55 vs 50), VOD (2 vs 0), or in infections
such as RSV (3 vs 1), VZV (1 vs 0), HSV (3 vs 8), Adenovirus (2 vs
1), polyoma/BK virus (18 vs 26), bacterial infection (49 vs 38), or
fungal infection (12 vs 7) in weekly versus by IgG levels respec-
tively. A higher incidence of para-influenza occurred in the
weekly group (9 vs 0, p 5 0.003) correlating with flu season.
IVIG cost in the weekly control group totaled AWP $924,408
vs $252,547, with overall savings of $671,816 in the IVIG by level
group.
Conclusion:With no difference in major complications, rate of in-
fection, and a significant savings in IVIG use, a change in institu-
tional practice was implemented. IgG levels are now monitored
monthly and replacement is done based on low IgG level.552
RETROSPECTIVE ANALYSIS OF THE INCIDENCE OF SYMPTOMATIC VE-
NOUS THROMBOEMBOLISM AMONG PATIENTS WITH HEMATOLOGIC
MALIGNANCY
Hills, H., Broyles, J., Oliphant, C., Stelts, S. Methodist University Hospi-
tal, Memphis, TN
A growing body of evidence shows similar or increased venous
thromboembolism (VTE) risk in specific hematologic malignancies,
but few recommendations for VTE prophylaxis in hematologic ma-
lignancy exist. This study will investigate the incidence and trends of
VTE among hematologic malignancy patients to identify patients at
higher risk of VTE.
Methods: Clinical data was collected retrospectively from 200 ad-
missions to Methodist University Hospital from December 2008
to October 2009 with primary or secondary diagnoses of hemato-
logic malignancy. The primary objective is the incidence of symp-
tomatic VTE. Secondary objectives include rate of appropriate
VTE prophylaxis, risk of VTE in patients receiving VTE prophy-
laxis, subgroup analyses to determine populations at higher risk for
VTE, length of stay with occurrence of symptomatic VTE, inci-
dence of VTE surrounding implementation of hospital-wide VTE
prophylaxis protocol, and all-cause mortality versus possible VTE-
associated deaths.Results: A total of 144 patients were represented in 200 admis-
sions included in this study. The most common diagnoses
included were non-Hodgkin’s lymphoma (NHL, 24.3%), multi-
ple myeloma (MM, 24.3%), and acute myelocytic leukemia
(AML, 18.1%), and a majority of patients were African Ameri-
can. In April 2009, an automated screening tool for VTE pro-
phylaxis was implemented that both assesses VTE risk and
bleeding risk and offers three elective therapy options for
VTE prophylaxis. Admissions were stratified according to the
implementation date (100 before, 100 after protocol). Twelve
VTE events were observed across all 200 admissions (6%).
Nine VTE occurred prior to the protocol and 3 occurred after
the prophylaxis protocol, not statistically significant. NHL
(13%), chronic myelocytic leukemia (CML, 12.5%), and Hodg-
kin’s lymphoma (HL, 8.3%) had the highest rates of VTE. VTE
prophylaxis use increased by 160% after implementation of the
VTE prophylaxis protocol, (p 5 0.003). Use of VTE prophy-
laxis was not associated with any decreased risk of VTE or
length of stay.
Conclusion: Incidence of VTE among the local malignant hematol-
ogy patient population is similar to previously reported data, with
highest VTE rates found in those patients with NHL, CML, and
HL. The apparent lack of efficacy of VTE prophylaxis in this study
may reflect either inaccurate current definitions of adequate VTE
prophylaxis or the practice of holding anticoagulants in the setting
of thrombocytopenia.553
VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM SURVEILANCE AND
INFECTION IN AUTOLOGOUS AND ALLOGENEIC TRANSPLANTATION
Trifilio, S., Mehta, J. Northwestern Memorial Hospital
Introduction: Colonization with Vancomycin-resistant Enterococ-
cus Faecium(VRE) places patients at increased risk for VRE infec-
tion. Variable rates of colonization and infection have been
reported for hematapoeticc stem cell transplantion recipients.
Herein we reivew VRE colonization rates amongst 882 autologous
and allogeniec HSCT recipients and assess for risk factors associated
with the development of VRE infection.
Methods:Medical records for 822 consecutive HSCT recipient in-
patient admissions between 8/2004 to 8/2008were reviewed for data.
Pharmacy records were utilized to obtain data formedication. All pa-
tients were screened for VRE upon admission and weekly thereafter.
All patients received acyclovir, azole antifungals and ciprofloxacin as
prophylaxis. Positive VRE BAL cultures were excluded from infec-
tion analysis. Chi-square analysis was used for statistical analysis.
This study was approved by NMH IRB.
Results:For 822HSCT recipients reviewed (207 allogeneic and 615
autologous), new colonization developed in 136 patients (17%),
while 41 patients were VRE colonized prior to admission. Overall
28 patients (3.4%) developed VRE infection (urine 5 11, blood 5
17, multiple 5 3. No correlation was observed between age, sex,
or administration of a neutropenic diet and VRE colonization or in-
fection. Allogeneic transplant(p5 .013), especially melphalan based
RIST was associated with increased VRE infection (p 5 .011). Co-
infection wth Strept Viridans occurred more frequently in VRE in-
fected patients(p 5 .0001). Prior VRE colonization occurred in
15/28 patients (54%) who developed VRE infection compared to
13/651 who did not.(p 5 .0001). Median time to infection was
10days. A correlation between C.Diff infection and VRE coloniza-
tion was identified(p 5 .0014). Almost all patients received wide
spectrum B-Lactam antibiotics and vancomycin, which may explain
the lack of correlation between these antibiotics and the develop-
ment of VRE, however prior exposure to caspofungin was observed
more frequently in patients with VRE infection(p 5 .0001). All
treated patients received linezolid. Time to engraft was the same
for auto and all patients, with or without VRE. Crude in-patient
overall mortality was significantly higher in patients with VRE
infections (p 5 .0002).
Conclusion: VRE colonization and infection increase morbidity
and mortality post HSCT. Heightened awareness and correction
